salvinorin a has been researched along with 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide in 2 studies
| Studies (salvinorin a) | Trials (salvinorin a) | Recent Studies (post-2010) (salvinorin a) | Studies (4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide) | Trials (4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide) | Recent Studies (post-2010) (4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide) |
|---|---|---|---|---|---|
| 247 | 7 | 128 | 279 | 0 | 85 |
| Protein | Taxonomy | salvinorin a (IC50) | 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0842 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0879 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 4.7722 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 3.601 | |
| Mu-type opioid receptor | Homo sapiens (human) | 1.8083 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0086 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 3.85 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 2.48 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 6.066 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Che, T; Kalinin, DV; Loser, K; Mykicki, N; Schepmann, D; Ständer, S; Tangherlini, G; Wünsch, B | 1 |
| Benaderet, TS; Bishop-Mathis, K; Dersch, CM; Partilla, JS; Prisinzano, TE; Rothman, RB; Simpson, DS; Wang, X; Xu, H | 1 |
2 other study(ies) available for salvinorin a and 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide
| Article | Year |
|---|---|
Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.
Topics: Animals; Antineoplastic Agents; Binding Sites; Encephalomyelitis, Autoimmune, Experimental; HEK293 Cells; Humans; Interferon-gamma; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Docking Simulation; Protein Structure, Tertiary; Quinoxalines; Receptors, Opioid, kappa; Signal Transduction; Structure-Activity Relationship; Th1 Cells | 2019 |
Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Benzamides; Blotting, Western; CHO Cells; Cricetinae; Cricetulus; Diterpenes, Clerodane; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine-2-Alanine; Ethylketocyclazocine; Etorphine; Female; Furans; Gene Expression; GTP-Binding Protein alpha Subunits, G12-G13; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Morphine; Oligopeptides; Piperazines; Pyrones; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2008 |